The latency of human immunodeficiency virus type 1 (HIV-1) is a major barrier to achieving an HIV-1 cure, as antiretroviral therapy does not target the latent virus. Virus-host interactions play an es
The use of siRNAs to knock down gene expression can potentially be an approach to treat various diseases. To avoid siRNA toxicity the less transcriptionally active H1 pol III promoter, rather than the
aSynthetic miRNA were designed to mimic the endogenous miRNA, with ‘+’ indicating the mature miRNA strand, and ‘–’ indicating the passenger strand. bnti-miR inhibitor oligonucleotides were designed co
